Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

2
CYD / China Yuchai International, Ltd / SHAH CAPITAL MANAGEMENT - AMENDMENT 9 (Activist Investment)

2018-05-28 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.9) SCHEDULE 13D/A CHINA YUCHAI INTERNATIONAL (Name of Issuer) Common Stock (Title of Class of Securities) G21082105 (CUSIP Number) Shah Capital Management 8601 Six Forks Road, Suite 630 Raleigh, NC 27615 Tel. No.: (919) 719-6360 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) May 23, 2018 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.
CYD

1
CYD / China Yuchai International, Ltd / SHAH CAPITAL MANAGEMENT - AMENDMENT 9 (Activist Investment)

2018-05-28 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.9) SCHEDULE 13D/A CHINA YUCHAI INTERNATIONAL (Name of Issuer) Common Stock (Title of Class of Securities) G21082105 (CUSIP Number) Shah Capital Management 8601 Six Forks Road, Suite 630 Raleigh, NC 27615 Tel. No.: (919) 719-6360 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) May 23, 2018 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.
CYD

5
CYD / China Yuchai International, Ltd FORM SD

2018-05-23 sec.gov
cyd-sd.htm UNITED STATES SECURITIES AND EXCHANGE C
CYD

2
CYD / China Yuchai International, Ltd FORM 20-F/A

2018-04-30 sec.gov
Form 20-F/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CYD

84
YPF upgraded to strong buy from outperform at Raymond James

2018-04-23 marketwatch
The top analyst upgrades, downgrades and other research calls from Thursday include Adtran, Alcoa, Clorox, Kinder Morgan, Lam Research, MGIC, Sprint and Walmart.
LRCX ADAP RDS.B RDS.A KMI.WS CHFN RDSB DSGX RDSA SEP KMI.PRA KMI TSEM RYDBF RYDAF KMR HZNP YPF CVB KMRFZ CYD

1
CYD / China Yuchai International, Ltd FORM 20-F

2018-04-16 sec.gov
Form 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CYD

0
BRIEF-MTU Yuchai Power Commences Mass Production Of MTU S4000 Series Engines

2018-04-16 reuters
* CHINA YUCHAI INTERNATIONAL - UNIT MTU YUCHAI POWER COMMENCED PRODUCTION OF MTU S4000 SERIES ENGINES IN ITS NEW FACILITY IN YULIN CITY, CHINA Source text for Eikon: Further company coverage: ([email protected])
CYD

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to CYD / China Yuchai International, Ltd on message board site Silicon Investor.

CYD - Net sales increase to RMB1.7 billion
CUSIP: G21082105